期刊文献+

CD147和HER-2在胃癌组织中的表达及其与预后的关系 被引量:6

下载PDF
导出
摘要 目的:探讨细胞外基质金属蛋白酶诱导因子(CD147)和人表皮生长因子受体-2(HER-2)在胃癌的表达及预后意义。方法:应用免疫组化法检测63例胃癌组织及40例癌旁正常组织中CD147和HER-2的表达,对随访资料进行生存分析。结果:胃癌组织中CD147和HER-2的阳性表达率分别为77.8%和34.9%,均高于癌旁正常组织中的表达率(25.0%和0%)(均P<0.05)。CD147的表达与肿瘤浸润深度、TNM分期、淋巴结转移和Ki-67增殖指数相关(P<0.05);HER-2的表达与淋巴结转移相关(P<0.05)。CD147和HER-2的表达呈正相关(r=0.311,P=0.013)。单因素生存分析显示CD147和HER-2表达阳性的胃癌患者生存率低于表达阴性组。结论:CD147和HER-2的表达与胃癌侵袭、转移和预后有关,两者可作为胃癌判断临床预后的参考指标。
出处 《实用医学杂志》 CAS 北大核心 2015年第18期3018-3021,共4页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1周明星,肖何.CD147、HER-2蛋白表达与胃癌侵袭转移的关系[J].临床与实验病理学杂志,2013,29(11):1250-1252. 被引量:7
  • 2苗杰.胃癌中HER-2、MT1-MMP及CD147蛋白的表达及意义[J].临床与实验病理学杂志,2012,28(12):1361-1364. 被引量:7
  • 3胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:97
  • 4Yu YH, Morales J, Feng L, et al. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(5):553- 565.
  • 5Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor eell proliferation, invasion and increases ehemosensitivity to eisplatin in SGC7901 cell in vitro [J]. J Exp Clin Cancer Res, 2010,29 ( 1 ) : 61-68.
  • 6Kwang KP, Song IY, Kyung WS, et al. Correlations of human epithelial growth factor receptor 2 overexpression with MUC2, MUC5AC, MUC6, p53, and elinieopathologieal characteristics in gastric cancer patients with curative resection [ J ]. Gastroenterol Res Praet, 2015,2015 : 946359.
  • 7Suzuki S, ]shikawa K. Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells [J].Int J Oncol,2014,44(3) : 912-917.
  • 8Gialeli Ch, Theoeharis AD, Kletsas D, et al. Expression of matrix maeromolecules and functional properties of EGF O responsive colon cancer ceils are inhibited by panitumumab [ J ]. Invest New Drugs, 2013,31 (3) : 516-524.

二级参考文献33

  • 1王建红,何松,陈冬梅,谭清和,龚振夏,朱亚芳.Her-2/neu基因过表达与胃癌生物学行为的关系研究[J].临床肿瘤学杂志,2006,11(2):105-109. 被引量:4
  • 2黄悦,赵建华,樊克武.CD147及MMP-2在胃癌中的表达及意义[J].肿瘤基础与临床,2007,20(1):21-23. 被引量:3
  • 3Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 4Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 5Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 6Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 7Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 8Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 9Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 10RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.

共引文献107

同被引文献41

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部